<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(26)</volume><submitter>You Y</submitter><pubmed_abstract>As one of the representative bioorthogonal reactions, the copper-catalyzed click reaction provides a promising approach for &lt;i>in situ&lt;/i> prodrug activation in cancer treatment. To solve the issue of inherent toxicity of Cu(i), biocompatible heterogeneous copper nanoparticles (CuNPs) were developed for the Cu-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. However, the unsatisfactory catalytic activity and off-target effect still hindered their application in biological systems. Herein, we constructed a DNAzyme-augmented and targeted bioorthogonal catalyst for synergistic cancer therapy. The system could present specificity to cancer cells and promote the generation of Cu(i) &lt;i>via&lt;/i> DNAzyme-induced value state conversion of DNA-templated ultrasmall CuNPs upon exposure to endogen</pubmed_abstract><journal>Chemical science</journal><pagination>7829-7836</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9258401</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>A DNAzyme-augmented bioorthogonal catalysis system for synergistic cancer therapy.</pubmed_title><pmcid>PMC9258401</pmcid><pubmed_authors>Liu H</pubmed_authors><pubmed_authors>You Y</pubmed_authors><pubmed_authors>Zhu J</pubmed_authors><pubmed_authors>Ren J</pubmed_authors><pubmed_authors>Qu X</pubmed_authors><pubmed_authors>Wang Y</pubmed_authors><pubmed_authors>Pu F</pubmed_authors></additional><is_claimable>false</is_claimable><name>A DNAzyme-augmented bioorthogonal catalysis system for synergistic cancer therapy.</name><description>As one of the representative bioorthogonal reactions, the copper-catalyzed click reaction provides a promising approach for &lt;i>in situ&lt;/i> prodrug activation in cancer treatment. To solve the issue of inherent toxicity of Cu(i), biocompatible heterogeneous copper nanoparticles (CuNPs) were developed for the Cu-catalyzed azide-alkyne cycloaddition (CuAAC) reaction. However, the unsatisfactory catalytic activity and off-target effect still hindered their application in biological systems. Herein, we constructed a DNAzyme-augmented and targeted bioorthogonal catalyst for synergistic cancer therapy. The system could present specificity to cancer cells and promote the generation of Cu(i) &lt;i>via&lt;/i> DNAzyme-induced value state conversion of DNA-templated ultrasmall CuNPs upon exposure to endogen</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Jul</publication><modification>2025-04-05T14:24:49.777Z</modification><creation>2025-04-05T14:24:49.777Z</creation></dates><accession>S-EPMC9258401</accession><cross_references><pubmed>35865897</pubmed><doi>10.1039/d2sc02050e</doi></cross_references></HashMap>